QGE031

Phase 2Small molecule

Novartis

QGE031 is one of 131 small molecule programs targeting Allergy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

130

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

Bullous PemphigoidActive, not recruiting

Allergic AsthmaActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

AllergyPhase 2

Active, not recruiting

Bullous PemphigoidPhase 2

Active, not recruiting

Allergic AsthmaPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

QGE031

Novartis

Phase 2

2 4

Spiriva

Boehringer Ingelheim

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Tylenol

KKenvue Brands

Preclinical

1 7

Aclidinium Bromide

AstraZeneca

Preclinical

—8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Spiriva

Boehringer Ingelheim

Preclinical

3 10

Inhaled Corticosteroids

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Asthma2 trials

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Terminated· Novartis logo

Novartis·Phase 2·NCT02075008·270 enrolled

A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma

Completed· Novartis logo

Novartis·Phase 1/2·NCT01703312·37 enrolled

Asthma2 trials

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

Completed· Novartis logo

Novartis·Phase 2·NCT01716754·471 enrolled

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Terminated· Novartis logo

Novartis·Phase 2·NCT02336425·10 enrolled

Bullous Pemphigoid1 trial

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Terminated· Novartis logo

Novartis·Phase 2·NCT01688882·20 enrolled

Allergy1 trial

Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy

Withdrawn· Novartis logo

Novartis·Phase 2·NCT01451450

Immunogenicity1 trial

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects

Completed· Novartis logo

Novartis·Phase 1·NCT01596712·209 enrolled

2 more indications

Efficacy and Safety1 trial

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Completed· Novartis logo

Novartis·Phase 2·NCT02477332·382 enrolled

Atopic Dermatitis1 trial

A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients

Completed· Novartis logo

Novartis·Phase 2·NCT01552629·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for QGE031. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QGE031 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QGE031. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

QGE031

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Asthma2 trials

Asthma2 trials

Bullous Pemphigoid1 trial

Allergy1 trial

Immunogenicity1 trial

Efficacy and Safety1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News